Overview

Extended Use of ModraDoc006/r

Status:
Completed

Trial end date:
2019-05-16

Target enrollment:

Participant gender:

Summary

This is a study for extended use of ModraDoc006/r in patients with advanced solid tumours, available after completed treatment in one of the phase I trials with ModraDoc006/r. The primary goal is to explore the safety of extended use.

Phase:

Phase 1

Details

Lead Sponsor:

Modra Pharmaceuticals

Treatments:

Docetaxel